Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical’s Phase II clinical trial of the KRAS G12C inhibitor, garsorasib, has demonstrated promising results in treating non-small cell lung cancer with an objective response rate of 50% and a disease control rate of 89%. Published in The Lancet Respiratory Medicine, the study indicates garsorasib was well-tolerated, with a higher tumor response and longer duration of response among patients. This breakthrough has positioned garsorasib for priority review in China, with international trials underway for various cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.